Cite
Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
MLA
Chaoui, Driss, et al. “Relapsed or Refractory Chronic Lymphocytic Leukemia Retreated with Rituximab in Daily Practice: Final Results of the PERLE Study.” Leukemia & Lymphoma, vol. 60, no. 6, June 2019, pp. 1563–67. EBSCOhost, https://doi.org/10.1080/10428194.2018.1533130.
APA
Chaoui, D., Hacini, M., Fitoussi, O., Karlin, L., Arkam, Y., Jourdan, E., Orfeuvre, H., Voillat, L., Sanhes, L., Leprêtre, S., Liu, K. L., Barry, M., Tempescul, A., Dilhuydy, M.-S., Chaib, A., Slama, B., Labourey, J. L., Benbrahim, O., Dreyfus, B., … Choquet, S. (2019). Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study. Leukemia & Lymphoma, 60(6), 1563–1567. https://doi.org/10.1080/10428194.2018.1533130
Chicago
Chaoui, Driss, Maya Hacini, Olivier Fitoussi, Lionel Karlin, Yazid Arkam, Eric Jourdan, Hubert Orfeuvre, et al. 2019. “Relapsed or Refractory Chronic Lymphocytic Leukemia Retreated with Rituximab in Daily Practice: Final Results of the PERLE Study.” Leukemia & Lymphoma 60 (6): 1563–67. doi:10.1080/10428194.2018.1533130.